- cafead Nov 30, 2023 at 10:22: AM
via Ascendis Pharma has pocketed $70 million in exchange for the Japanese rights to the FDA-approved long-acting growth hormone Skytrofa and two other hormone drugs.
Beyond the upfront payment, Teijin Pharma has pledged up to $175 million in development and regulatory milestones as well as additional commercial milestones and royalties that could reach up to the mid-20s per cent.
article source
Beyond the upfront payment, Teijin Pharma has pledged up to $175 million in development and regulatory milestones as well as additional commercial milestones and royalties that could reach up to the mid-20s per cent.
article source